Source Code Capital portfolio company Jianhai Technology announced the completion of a 150 million yuan Series B investment, with existing shareholder Source Code Capital continuing to increase its stake.

源码资本·March 23, 2021·0·5

Dedicated to advancing post-diagnosis disease management systems for patients, it has already partnered with more than 1,000 hospitals.

On March 22, 2021, Hangzhou Jianhai Technology Co., Ltd. ("Jianhai Technology") completed a RMB 150 million Series B round led by HSG, with Source Code Capital and Sherpa Capital participating. Probe Capital served as the exclusive financial advisor. Source Code Capital had previously led the company's Series A3 round.

Founded in 2015, Jianhai Technology focuses on building and operating post-diagnosis disease management services, and has already partnered with over 1,000 hospitals. Guided by the mission of "making care a powerful remedy," the company is dedicated to advancing patient post-diagnosis disease management systems and delivering better quality of life and safer medical services to patients.

The new funding will support the development of an ecosystem for post-diagnosis disease management infrastructure and service operations. After years of deep engagement in the post-diagnosis healthcare space, Jianhai Technology has launched its "C.S.D" product suite to build foundational infrastructure for hospital post-diagnosis disease management: the "C Series" for collaborative disease management services, the "S Series" for intelligent patient service platforms, and the "D Series" for digital therapeutics platforms and research. The approach centers on data as core intellectual property, uses AI to unlock industry efficiency, builds commercial viability through services, and establishes a digital therapeutics ecosystem through community operations.